Press Releases

Year

June 24, 2024

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH) Complement factor H (CFH) variants with reduced function are a well-validated genetic risk factor for geographic

June 18, 2024

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye) Clinical data will be presented by Raj K. Maturi, M.D., a Principal Investigator in the PRISM study, at the American Society of Retina

June 8, 2024

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the standard bimonthly aflibercept control group at all six timepoints through Week 24

June 6, 2024

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

Clinically meaningful improvements in ppFEV 1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV 1 50-80%) and >6 months follow up Aerosolized 4D-710 was well tolerated at doses up to 1E15 vg (n=6) Dose-dependent and widespread

June 4, 2024

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden to be presented in oral presentation EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 4D

June 3, 2024

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will

May 30, 2024

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference

Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47 th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m. BST Company to host webcast on Thursday, June 6, 2024 at 8:00 a.m.

May 9, 2024

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025 Interim 24-week landmark analysis from PRISM Phase 2 Population Extension

May 7, 2024

4DMT to Participate in Upcoming Investor Conference

EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will

May 1, 2024

4DMT Announces Presentations at ARVO 2024 Annual Meeting

Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation 4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT,

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page

About 4DMT

Navigation

Location